• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新发房颤后抗凝延迟的相关因素

Factors Associated with Anticoagulation Delay Following New-Onset Atrial Fibrillation.

作者信息

Khurshid Shaan, Weng Lu-Chen, Hulme Olivia L, Ellinor Patrick T, Lubitz Steven A

机构信息

Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts.

Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Am J Cardiol. 2017 Oct 15;120(8):1316-1321. doi: 10.1016/j.amjcard.2017.07.017. Epub 2017 Jul 24.

DOI:10.1016/j.amjcard.2017.07.017
PMID:28823487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5657547/
Abstract

Oral anticoagulation (OAC) is effective yet reportedly underutilized for stroke prevention in atrial fibrillation (AF). Factors associated with delayed OAC after incident AF are unknown. Using a large electronic medical record, we identified incident episodes of AF diagnosed in 2006 to 2014 using a validated algorithm. Among patients with a Congestive heart failure, Hypertension, Age, Diabetes, and Stroke (CHADS) score ≥1 started on OAC within 1 year, we examined baseline characteristics at AF diagnosis and their association with time to OAC using multivariable Cox proportional hazards modeling. Of 4,388 patients with incident AF and CHADS score ≥1 who were started on OAC within 1 year, the mean age was 72.6, and 41% were women. Median time to OAC was 5 days (interquartile range 1 to 43), and most patients received warfarin (86.3%). Among patients without prevalent stroke, 98 strokes (2.2% of the sample) occurred between AF diagnosis and OAC initiation. In multivariable analyses, several factors were associated with delayed OAC including female gender (hazard ratio [HR] 1.08, 95% confidence interval [CI] 1.01 to 1.15), absence of hypertension (HR 1.15, 95% CI 1.03 to 1.27), previous fall (HR 1.53, 95% CI 1.08 to 2.17), and chronic kidney disease (HR 1.12, 95% CI 1.04 to 1.21). Among women, OAC prescription at 1, 3, and 6 months was 70.0%, 81.7%, and 89.5%, respectively, whereas for men, OAC prescription was 73.4%, 84.0%, and 91.5%, respectively. Most patients with new AF and elevated stroke risk started on OAC receive it within 1 week, although the promptness of initiation varies. The stroke rate is substantial in the period between AF diagnosis and OAC initiation. Interventions targeting identified risk factors for delayed OAC may result in improved outcomes.

摘要

口服抗凝药(OAC)对预防心房颤动(AF)导致的中风有效,但据报道其使用率不足。AF发病后OAC延迟使用的相关因素尚不清楚。我们利用大型电子病历,通过验证算法识别出2006年至2014年诊断的AF发病事件。在1年内开始使用OAC且充血性心力衰竭、高血压、年龄、糖尿病和中风(CHADS)评分≥1的患者中,我们在AF诊断时检查了基线特征,并使用多变量Cox比例风险模型研究了这些特征与开始使用OAC时间的关联。在4388例1年内开始使用OAC的AF发病且CHADS评分≥1的患者中,平均年龄为72.6岁,41%为女性。开始使用OAC的中位时间为5天(四分位间距为1至43天),大多数患者接受华法林治疗(86.3%)。在无既往中风的患者中,98例中风(占样本的2.2%)发生在AF诊断至开始使用OAC之间。在多变量分析中,几个因素与OAC延迟使用有关,包括女性(风险比[HR]1.08,95%置信区间[CI]1.01至1.15)、无高血压(HR 1.15,95%CI 1.03至1.27)、既往跌倒(HR 1.53,95%CI 1.08至2.17)和慢性肾病(HR 1.12,95%CI 1.04至1.21)。在女性中,1个月、3个月和6个月时OAC处方率分别为70.0%、81.7%和89.5%,而男性分别为73.4%、84.0%和91.5%。大多数有新发AF且中风风险升高并开始使用OAC的患者在1周内接受了治疗,尽管开始治疗的及时性有所不同。在AF诊断至开始使用OAC期间中风发生率较高。针对已确定的OAC延迟使用风险因素进行干预可能会改善预后。

相似文献

1
Factors Associated with Anticoagulation Delay Following New-Onset Atrial Fibrillation.新发房颤后抗凝延迟的相关因素
Am J Cardiol. 2017 Oct 15;120(8):1316-1321. doi: 10.1016/j.amjcard.2017.07.017. Epub 2017 Jul 24.
2
Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS to the CHADS-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry.在采用CHADS-VASc评分替代CHADS评分进行血栓栓塞风险评估的指南推荐更改后,低至中度卒中风险心房颤动患者口服抗凝药处方的当代趋势:来自国家心血管数据注册中心门诊实践创新与临床卓越心房颤动注册研究的分析
Circ Cardiovasc Qual Outcomes. 2017 May;10(5). doi: 10.1161/CIRCOUTCOMES.116.003476.
3
Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation.装置检测到的心房颤动抗凝治疗的处方变化与结局的实践差异。
Circulation. 2019 May 28;139(22):2502-2512. doi: 10.1161/CIRCULATIONAHA.118.038988. Epub 2019 Mar 17.
4
Factors Influencing Oral Anticoagulation Prescription for Patients Presenting to Emergency Departments With Atrial Fibrillation and Flutter.影响因房颤和房扑急诊就诊患者口服抗凝药物处方的因素。
Can J Cardiol. 2018 Jun;34(6):804-807. doi: 10.1016/j.cjca.2018.03.009. Epub 2018 Mar 24.
5
Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation.医疗保险受益人群新诊断心房颤动后抗凝治疗的依从性与卒中风险。
Am J Cardiovasc Drugs. 2020 Apr;20(2):199-207. doi: 10.1007/s40256-019-00371-3.
6
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.在接受抗凝治疗的房颤患者中,HAS-BLED 评分对大出血的预测准确性优于 CHADS2 或 CHA2DS2-VASc 评分。
J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18.
7
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.心房颤动抗凝治疗的风险与获益:来自心房颤动更明智治疗结局登记研究(ORBIT - AF)登记处的见解
Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):461-9. doi: 10.1161/CIRCOUTCOMES.113.000127. Epub 2013 Jun 11.
8
Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.停止口服抗凝治疗是房颤患者中风和死亡的一个重要危险因素。
Thromb Haemost. 2017 Jun 27;117(7):1448-1454. doi: 10.1160/TH16-12-0961. Epub 2017 Mar 23.
9
Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants.与直接口服抗凝剂引入相关的基层医疗网络中房颤患者抗凝治疗使用情况的变化
Am J Cardiol. 2017 Sep 1;120(5):786-791. doi: 10.1016/j.amjcard.2017.05.055. Epub 2017 Jun 15.
10
Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.口服抗凝药与伴有 1 项以上卒中危险因素的心房颤动患者卒中或死亡的风险:卢瓦尔河谷心房颤动项目。
Chest. 2016 Apr;149(4):960-8. doi: 10.1378/chest.15-1622. Epub 2016 Jan 12.

引用本文的文献

1
Impact of an Organized Treatment Pathway on Management of Atrial Fibrillation: The ER2EP Study.有组织的治疗路径对心房颤动管理的影响:ER2EP研究。
JACC Adv. 2024 Mar 21;3(5):100905. doi: 10.1016/j.jacadv.2024.100905. eCollection 2024 May.
2
Survey of Using Oral Anticoagulants in Patient with Non-valvular Atrial Fibrillation.非瓣膜性心房颤动患者口服抗凝剂使用情况调查。
Med Arch. 2024;78(1):16-21. doi: 10.5455/medarh.2024.78.16-21.
3
Factors associated with oral anticoagulant prescription status among patients with a new diagnosis of atrial fibrillation.

本文引用的文献

1
Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke.阿司匹林替代口服抗凝药物用于有卒中风险的房颤患者
J Am Coll Cardiol. 2016 Jun 28;67(25):2913-23. doi: 10.1016/j.jacc.2016.03.581.
2
A Simple and Portable Algorithm for Identifying Atrial Fibrillation in the Electronic Medical Record.一种用于在电子病历中识别心房颤动的简单便携式算法。
Am J Cardiol. 2016 Jan 15;117(2):221-5. doi: 10.1016/j.amjcard.2015.10.031. Epub 2015 Nov 6.
3
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
与新诊断为心房颤动的患者口服抗凝药物处方状况相关的因素。
Clin Cardiol. 2023 Aug;46(8):937-941. doi: 10.1002/clc.24077. Epub 2023 Jul 4.
4
Clinical outcomes in patients with atrial fibrillation and a history of falls using non-vitamin K antagonist oral anticoagulants: A nationwide cohort study.使用非维生素K拮抗剂口服抗凝剂的房颤合并跌倒史患者的临床结局:一项全国性队列研究。
Int J Cardiol Heart Vasc. 2023 May 18;47:101223. doi: 10.1016/j.ijcha.2023.101223. eCollection 2023 Aug.
5
Factors Associated with Falls During Hospitalization for Coronavirus Disease 2019 (COVID-19).与 2019 年冠状病毒病(COVID-19)住院期间跌倒相关的因素。
Med Sci Monit. 2022 May 27;28:e936547. doi: 10.12659/MSM.936547.
6
Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.在心房颤动患者中从维生素 K 拮抗剂转换为非维生素 K 拮抗剂口服抗凝剂:预测因素、模式和时间趋势。
BMC Cardiovasc Disord. 2021 Oct 13;21(1):493. doi: 10.1186/s12872-021-02295-w.
7
Atrial Fibrillation Diagnosis using ECG Records and Self-Report in the Community: Cross-Sectional Analysis from ELSA-Brasil.基于社区心电图记录和自我报告的心房颤动诊断:ELSA-Brasil 的横断面分析。
Arq Bras Cardiol. 2021 Sep;117(3):426-434. doi: 10.36660/abc.20190873.
8
Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the CHEST Score: The West Birmingham Atrial Fibrillation Project.利用 CHEST 评分识别持续性心房快速性心律失常的高危患者:西伯明翰心房颤动项目。
J Am Heart Assoc. 2021 Mar 16;10(6):e017519. doi: 10.1161/JAHA.120.017519. Epub 2021 Mar 5.
9
Anticoagulant Therapy for Frail Patients with Atrial Fibrillation.衰弱患者心房颤动的抗凝治疗。
Intern Med. 2021;60(4):495-506. doi: 10.2169/internalmedicine.6077-20. Epub 2021 Feb 15.
10
Sex Differences in the Repair of Retinal Detachments in the United States.美国视网膜脱离修复中的性别差异。
Am J Ophthalmol. 2020 Nov;219:284-294. doi: 10.1016/j.ajo.2020.06.039. Epub 2020 Jul 5.
2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南:美国心脏病学会/美国心脏协会实践指南工作组及心律学会的报告
J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28.
4
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.华法林与新型口服抗凝剂治疗心房颤动和静脉血栓栓塞症的疗效比较:系统评价。
Ann Intern Med. 2012 Dec 4;157(11):796-807. doi: 10.7326/0003-4819-157-10-201211200-00532.
5
The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.CHA2DS2-VASc 评分在 CHADS2 评分为 0-1 的房颤患者中对卒中风险分层的价值:一项全国性队列研究。
Thromb Haemost. 2012 Jun;107(6):1172-9. doi: 10.1160/TH12-03-0175. Epub 2012 Apr 3.
6
Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients.德国心房颤动患者的口服抗凝治疗。基于 183448 名患者的理赔数据,评估抗凝不足的原因及其临床结局,并探讨其与指南的一致性。
Thromb Haemost. 2012 Jun;107(6):1053-65. doi: 10.1160/TH11-11-0768. Epub 2012 Mar 8.
7
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.评估 182678 例心房颤动患者缺血性卒中和出血的风险分层方案:瑞典心房颤动队列研究。
Eur Heart J. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. Epub 2012 Jan 13.
8
Risk of stroke after surgery in patients with and without chronic atrial fibrillation.有和无慢性心房颤动患者手术后中风的风险。
J Thromb Haemost. 2010 May;8(5):884-90. doi: 10.1111/j.1538-7836.2010.03781.x. Epub 2010 Jan 24.
9
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.采用新型基于风险因素的方法对房颤患者的卒中与血栓栓塞风险进行临床分层的研究:房颤的欧洲心脏调查。
Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.
10
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.美国心脏病学会/美国心脏协会/欧洲心脏病学会2006年心房颤动患者管理指南:美国心脏病学会/美国心脏协会实践指南工作组和欧洲心脏病学会实践指南委员会(修订2001年心房颤动患者管理指南写作委员会)报告:与欧洲心律协会和心律协会合作制定。
Circulation. 2006 Aug 15;114(7):e257-354. doi: 10.1161/CIRCULATIONAHA.106.177292.